COMMUNIQUÉS West-GlobeNewswire

Brain Cancer Canada Awards $80,000 towards Adolescent and Young Adult (AYA) Brain Cancer Research
29/05/2024
TORONTO, May 29, 2024 (GLOBE NEWSWIRE) -- Brain Cancer Canada (BCC) is proud to announce the final grant in a series of four issued this May for Brain Cancer Awareness Month, “Go Grey in May.” The latest $80,000.00 [...]
MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix
29/05/2024
Immediate opportunity to increase capacity for formulation and early asset development in upgraded Boston area R&D space Non-cash deal includes royalty-free iSPERSE ™ technology license in exchange for access to [...]
NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials
29/05/2024
TORONTO and HAIFA, Israel, May 29, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company developing regenerative [...]
Spectral AI Set to Join Russell Microcap® Index
29/05/2024
DALLAS, May 29, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment [...]
Le flux de travail CellEDIT de Cytosurge, basé sur sa technologie exclusive FluidFM®, reçoit une validation dans une publication évaluée par des pairs.
29/05/2024
Le service CellEDIT représente un nouveau flux de travail tirant parti de la nanoinjection intranucléaire de composants CRISPR/Cas9 dans des cellules uniques, par l’intermédiaire de la technologie FluidFM. Le contrôle [...]
Cytosurge's CellEDIT Workflow, based on its Proprietary FluidFM® Technology, Receives Validation in Peer-Reviewed Publication
29/05/2024
CellEDIT Service represents a novel workflow leveraging FluidFM-mediated intranuclear nanoinjection of CRISPR/Cas9 components into single cells. Control of the amount and stoichiometry of RNP complexes could boost [...]
Artelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24
29/05/2024
ART12.11 demonstrates comparable pharmacokinetics compared to Epidiolex® SOLANA BEACH, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused [...]
Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th
29/05/2024
GLEN ALLEN, Va., May 29, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and [...]
Intelligent Bio Solutions Successfully Completes Recruitment and Begins Subject Screening for FDA 510(k) Pharmacokinetic (PK) Study
29/05/2024
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today [...]
Penn Presbyterian Medical Center Becomes First Hospital in the Northeast to Adopt Advanced Robotic Technology for Heart Treatment
29/05/2024
ST. LOUIS, May 29, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announces the successful treatment of the first heart rhythm [...]
RespireRx Pharmaceuticals Inc. Announces a Department of Defense Award to Fund a Phase 2 Clinical Study to Determine the Safety and Efficacy of CX1739, its Lead AMPAkine, to Improve Bladder Function in Patients with Spinal Cord Injury
29/05/2024
Glen Rock, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Markets: RSPI) (RespireRx or the Company), focused on the discovery and development of innovative and revolutionary treatments [...]
IHH reports highest ever quarterly revenue in Q1 2024, with double-digit growth across key metrics, on outstanding performance across all markets
29/05/2024
KUALA LUMPUR, Malaysia and SINGAPORE, May 29, 2024 (GLOBE NEWSWIRE) -- Revenue at RM6.0 billion mark for the first time Outstanding growth momentum: revenue up 16%, EBITDA up 19% Core profit or PATMI (ex EI) up 22%; [...]
MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference
29/05/2024
ROCKVILLE, Md., May 29, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and [...]
Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024
29/05/2024
REYKJAVIK, Iceland, May 29, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its [...]
Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024
29/05/2024
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies Healthcare Conference [...]
Intra-Cellular Therapies to Present at the Jefferies Global Healthcare Conference
29/05/2024
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) [...]
BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem
29/05/2024
BioNTech and CEPI aim to enhance local R&D, clinical and commercial-scale manufacturing capacities to develop potential mRNA vaccines in Africa, for Africa CEPI to fund up to $145 million to support BioNTech in [...]
KALA BIO to Present at Jefferies Global Healthcare Conference
29/05/2024
ARLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare [...]
Bluejay Therapeutics Receives Positive Opinion on Orphan Designation from the European Medicines Agency for BJT-778 for the Treatment of Chronic Hepatitis D
29/05/2024
SAN MATEO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, a private clinical-stage biopharmaceutical company focused on viral and liver diseases with unmet medical needs, today announced that the [...]

Pages